In Brief
Wang et al. describe the challenges faced by case-control studies of rare variants. The inability to accurately determine allele frequencies, variability in control frequencies between populations, and admixture of clinical phenotypes renders them unsuitable for the replication of familial studies.
INTRODUCTION
Regarding the opinion presented by Dr. Cotsapas on behalf of the IMSGC (The International Multiple Sclerosis Genetics Consortium, 2016 ) that the inability to identify an association between NR1H3 p.R415Q and multiple sclerosis (MS) in their large genome-wide association study (GWAS) contradicts the claim that this mutation is responsible for disease in two MS families, we respectfully disagree (Wang et al., 2016) . Although GWASs have been very successful for the identification of common genetic variants that increase the susceptibility to MS (Beecham et al., 2013) , they are underpowered for the identification or replication of mutations with very low frequencies. The identification of genes and mutations for familial forms of complex diseases has been challenging, and despite the creation of very large MS consortia, case-control studies have been unsuccessful in this regard. The study of multi-incident MS families provides a complementary approach to the IMSGC efforts for a better understanding of the genetic components implicated in the onset of MS, and these efforts should not be simply dismissed on account of a lack of association.
RESULTS AND DISCUSSION
If we look at the data closely, in the case-control analysis the IMSGC identified 31 carriers of the NR1H3 p.R415Q mutation in 32,852 cases (minor allele frequency [MAF] = 0.00050) and 31 carriers in 36,538 controls (MAF = 0.00045). While one would indeed expect a pathogenic mutation with reduced penetrance to be more prevalent in cases than controls, the critical factor is how much higher this frequency should be, and whether the IMSGC could detect a significant difference in their cohort. Assuming that the penetrance observed in our families (7/11) is representative of the general population, and given the IMSGC case-control ratio (1:1.11), we would expect 38 of the 62 NR1H3 p.R415Q carriers identified in the IMGSC study to have developed MS. In other words, it is only necessary for seven control samples with the NR1H3 mutation to develop MS, at some point in their life, for the IMSGC data to exactly match what would have been expected from our familial study. In addition, the number of carrier cases and controls observed by the IMSGC and those expected based on the above calculations are not statistically different (p = 0.34). It is important to note that several of the IMSGC groups use convenience control samples not assessed for neurological disease or family history of MS, which may be contributing to a higher than expected control frequency (Beecham et al., 2013) .
The low NR1H3 p.R415Q allele frequency renders the IMSGC cohort with 0.09% power to identify a significant association between this mutation and MS, assuming the described cohort size (69,390) and allele frequency (0.00047), genome-wide significance (10 À8 ), and an odds ratio of 1.76 (as estimated from the penetrance observed in families) (Purcell et al., 2003) . To achieve 80% power, the IMSGC study would require 434,000 samples. Even when considering a nominally significant association (p = 0.05), the power of their study is only 74.7%. Thus, the lack of significant association in the IMSGC study is not in opposition to the suggested pathogenicity of NR1H3 p.R415Q. The presence of mutation carriers in control subjects is also discussed in the letter by Minikel and MacArthur (2016) .
The frequency for NR1H3 p.R415Q in the ExAC non-Finnish European population is 0.00031 (Lek et al., 2016) , which is not statistically different from the frequency of 0.00048 observed in our study (Wang et al., 2016) . However, despite not being statistically significant, this frequency is enriched by 55% in MS patients compared to ExAC. The letter describes the contribution of NR1H3 to MS using an estimated odds ratio of 399, which is orders of magnitude higher than the odds ratio observed for well-described mutations for adult-onset diseases (Clark et al., 2006; Smith et al., 2015) . This extremely high odds ratio highlights the caveat of performing prediction estimates based on data that are very likely inaccurate. Similar to the controls used by the IMSGC, the populations analyzed by the ExAC are not disease-free, and therefore, the reported frequencies, particularly for rare variants, might be inflated and should be considered with caution. The NR1H3 p.R415Q frequency in the ExAC database may be higher than expected for true healthy controls, given the inclusion of samples from projects studying diseases with an immune component, such as diabetes and inflammatory bowel disease, as well as cholesterol metabolism, such as myocardial infarction and atherosclerosis: diseases and biological pathways in which NR1H3 has been shown or suggested to play a role (Huang and Chen, 2016; Parikh et al., 2014; Pickup, 2004; Poli et al., 2013; Tall and Yvan-Charvet, 2015) .
The inherent inaccuracy in determining rare variant frequencies and the use of diseased control groups indicate that IMSGC and ExAC allele frequencies may not be suitable for assessing disease risk contribution for pathogenic mutations identified in familial studies. This is further evidenced by the variant frequencies observed in the four IMSGC control populations with more than 10,000 samples, which range between 0.00026 and 0.00064, a 2.5-fold difference. The inconsistency between ExAC and IMSGC control populations, and within the IMSGC, highlights the difficulty in obtaining accurate frequencies for rare variants and/or accurate population-specific frequencies, and shows the challenges faced by GWASs and populationbased studies of rare variants.
The IMSGC suggests that lack of a significant LOD score at the NR1H3 locus in 40 CCPGSMS families and over 700 IMSGC families challenges the finding that this locus contains a pathogenic mutation. Linkage analysis can lead to a significant LOD score in two situations: (1) when a highly penetrant mutation segregates with disease in a large family, and/or (2) when several small families with the same pathogenic mutation, or different mutations in the same locus, are analyzed together (Ott, 1989) . Given that NR1H3 p.R415Q has reduced penetrance and a very low allele frequency, which suggests that none of the 700 IMSGC families would be expected to have this mutation (0.0005 3 700 3 2 = 0.7), it is very unlikely that these linkage studies would produce a significant LOD score at this locus. Therefore, the lack of a significant LOD score in previous studies does not rule out a pathogenic role in the two reported families. Regarding our linkage analysis, a LOD score over 3 is considered significant, and a LOD score between 1.86 and 3 is considered suggestive (Nyholt, 2000) ; therefore, the LOD score of 2.2 observed in our families is suggestive of linkage and consistent with how we described our outcome: ''suggesting this genomic region as the disease locus for these families.''
In our original article, we identified an association between a common variant in NR1H3 (rs2279238) and primary-progressive MS (PPMS). The statistical correction typically implemented in association studies is the Bonferroni method, in which the alpha value (0.05) is divided by the number of comparisons performed to set the appropriate significance threshold and to minimize spurious positive associations (Armstrong, 2014; Dunn, 1961) . A GWAS approach requires a stringent significance threshold (10 À8 ), given that the methodology involves the analyses of millions of SNPs and needs to address multiple-comparison correction. Similarly, in our study Bonferroni correction was applied to meet a rigorous threshold of significance. Given that we analyzed five SNPs, the appropriate significance threshold after accounting for multiple testing is 0.01 (0.05/5). The IMSGC analysis identified a variant (rs3824866) in complete linkage disequilibrium (LD) with rs2279238 associated with MS risk, thus confirming the association described in our study. These two variants are also in high LD (r 2 = 0.62) with an AGBL2 rs7120737 variant found to associate with MS risk in the IMSGC GWAS (Beecham et al., 2013) , and conditioning on this variant explains the association at this locus. Conditioning analysis does not provide a hierarchy of which variant is more likely responsible for an observed association; it indicates that the association identified by both variants is not independent, and therefore, they have both identified the same locus (Yang et al., 2012) . Neither of the associated variants is likely to be functionally relevant or the primary cause for association, given that the AGBL2 variant is intronic and the NR1H3 variant causes a synonymous substitution, and thus the biologically important variant in this associated locus remains to be identified. We propose that both our study and the IMSGC findings support a role for common genetic variation at the NR1H3 locus in MS risk, given its higher odds ratio compared to AGBL2 (1.35 versus 1.10).
Finally, the IMSGC also looked at whether the NR1H3 p.R415Q mutation associates with disease course. Although their analysis did not result in a statistically significant outcome, likely due to further reduced statistical power in this subset of patients, the frequency of NR1H3 p.R415Q in PPMS patients appears to be higher than the frequency in relapsing-remitting MS (RRMS) in most of the IMSGC populations. This observation, albeit not significant, is consistent with the clinical phenotype (PPMS) observed in the two original families (Wang et al., 2016) . These data suggest that the lack of association between MS patients and controls in the IMSGC study may be explained by Simpson's paradox (Herná n et al., 2011) . If NR1H3 p.R415Q is relevant primarily for PPMS patients, who account for only 9.4% of those in the IMSGC cohort, the remaining 90.6% of patients can be expected to have allele frequencies similar to that observed in the general population, which would mask a true association between NR1H3 p.R415Q and patients with progressive disease.
In conclusion, we believe the assessment of rare variants in families has been consistently and extensively praised for its success (Ku et al., 2011; Rabbani et al., 2012; Stranneheim and Wedell, 2016) and has led to the identification of hundreds of genes and pathogenic mutations for many diseases (Hor et al., 2015; Johnson et al., 2010 Johnson et al., , 2014 Ng et al., 2010; Quadri et al., 2013; Sambuughin et al., 2015; Vilariñ o-G€ uell et al., 2011 Vilariñ o-G€ uell et al., , 2014 . This well-established approach does not represent ''an error in logic'' but rather tackles an important question from a different angle, filling in potential gaps that may occur with a GWAS approach. As stated in our original article, replication of our study is necessary to confirm NR1H3 p.R415Q as pathogenic mutation for MS. However, the replication provided by the IMSGC is limited by the use of convenience data in a casecontrol design to replicate a familial study. A more suitable approach by the IMSGC to replicate our findings might be to assess the segregation of NR1H3 p.R415Q in additional family members from the 31 MS patients they have identified with the mutation. This additional analysis could provide an appropriate replication of our initial study.
